다발성 골수종 시장 : 세계 규모, 점유율, 동향 분석, 기회, 예측 리포트(2019-2029년)

Global Multiple Myeloma Market Size Grows at Steady CAGR of 5.39% to Reach USD 29.4 Billion by 2029.

Global multiple myeloma market is flourishing because of the growing focus on the treatment and management of increasing incidences of multiple myeloma globally and rapid advancements in targeted drugs.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global multiple myeloma market size at USD 21.46 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global multiple myeloma market size to grow at a significant CAGR of 5.39% reaching a value of USD 29.4 billion by 2029. Major growth drivers for the global multiple myeloma market include the increasing adoption of microRNA therapies. These innovative treatment modalities harness the potential of microRNAs to regulate gene expression and oversee diverse cellular processes. The evolution of precisely targeted microRNA therapies holds promise for delivering more individualized and accurate treatments for multiple myeloma. Furthermore, the ascent of advanced biomedicine platforms plays a pivotal role in propelling the expansion of the multiple myeloma market. These multifaceted platforms encompass a wide spectrum of technologies and methodologies that facilitate the understanding of the molecular foundations of the disease, the identification of novel therapeutic targets, and the development of more effective treatment approaches. By harnessing the capabilities of these sophisticated platforms, researchers and healthcare professionals can delve deeper into the intricacies of multiple myeloma, thereby advancing the creation of groundbreaking therapeutic interventions. However, high treatment costs and stringent regulatory requirements are anticipated to restrain the overall market growth during the forecast period.

Global Multiple Myeloma Market - Overview:

The global multiple myeloma market refers to the collective economic and commercial landscape associated with the diagnosis, treatment, and management of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The market encompasses various pharmaceutical products, medical devices, diagnostic tools, research initiatives, and healthcare services related to multiple myeloma. It involves the production, distribution, and consumption of drugs, therapies, and technologies aimed at preventing, controlling, or curing multiple myeloma, as well as efforts to enhance patient care, improve outcomes, and advance scientific understanding of the disease. The global multiple myeloma market is influenced by medical advancements, regulatory policies, research and development activities, and the demand for innovative treatment approaches in the global healthcare industry.

Impact of COVID-19 on Global Multiple Myeloma Market

COVID-19 pandemic adversely affected the global multiple myeloma market. The crisis disrupted supply chains, delayed clinical trials, and redirected healthcare resources toward managing the pandemic. Multiple myeloma patients faced challenges in accessing treatments and medical care due to overwhelmed healthcare systems and safety concerns. Telemedicine gained prominence for consultations, but in-person treatments and clinical assessments were often delayed. Additionally, financial strains on healthcare systems affected research funding and hindered the development of new therapies. Despite these setbacks, the pandemic accelerated digital health adoption and emphasized the importance of resilient healthcare systems. The Global Multiple Myeloma Market is adapting to these challenges, but its growth trajectory was undoubtedly impacted by the pandemic.

Global Multiple Myeloma Market - By Treatment

Based on treatment, the global multiple myeloma market is divided into Chemotherapy, Targeted Therapy, Immunomodulatory Drugs, Steroids, Bone-modifying Drugs, Immunotherapy, Bone Marrow/Stem Cell Transplantation, Radiation Therapy, and Surgery segments. The immunomodulatory drugs segment holds the highest share in the global multiple myeloma market by treatment. The prominence of immunomodulators in the market is attributed to various factors, including the increasing prevalence of multiple myeloma and the rising demand for these drugs. Immunomodulators play a crucial role in modifying or delaying the progression of autoimmune, inflammatory, and cancerous conditions, with notable drugs, such as Thalomid, Revlimid, and pomalyst, being used for multiple myeloma treatment. The growing incidence of multiple myeloma is a primary driver, with lenalidomide, an immunomodulatory drug, demonstrating improved outcomes in studies, enhancing progression-free survival, response depth, and overall survival rates. This is expected to boost its adoption among patients and stimulate market growth. Also, increased research and development efforts and a rising number of drug approvals further contribute to market expansion.

Competitive Landscape:

Major players operating in the global multiple myeloma market include: Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, ONO Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Ltd, and Roche Group. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Multiple Myeloma Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Multiple Myeloma Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Multiple Myeloma Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. The rising incidence of Multiple Myeloma globally
    • 3.2.1.2. Advancements in targeted drugs
  • 3.2.2. Restraints
    • 3.2.2.1. High treatment costs
    • 3.2.2.2. Stringent regulatory requirements
  • 3.2.3. Opportunities
    • 3.2.3.1. Emerging markets
    • 3.2.3.2. Personalized medicine
  • 3.2.4. Challenges
    • 3.2.4.1. Competition
    • 3.2.4.2. Drug resistance
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Multiple Myeloma Market Overview

• 4.1. Market Size & Forecast, 2019-2029
  • 4.1.1. By Value (USD Billion)
• 4.2. Market Share and Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Smoldering (indolent) Multiple Myeloma
    • 4.2.1.2. Active (symptomatic) Multiple Myeloma
  • 4.2.2. By Treatment
    • 4.2.2.1. Chemotherapy
    • 4.2.2.2. Targeted Therapy
    • 4.2.2.3. Immunomodulatory Drugs
    • 4.2.2.4. Steroids
    • 4.2.2.5. Bone-modifying Drugs
    • 4.2.2.6. Immunotherapy
    • 4.2.2.7. Bone Marrow/Stem Cell Transplantation
    • 4.2.2.8. Radiation Therapy
    • 4.2.2.9. Surgery
    • 4.2.2.10. Others
  • 4.2.3. By Diagnosis
    • 4.2.3.1. Blood & Urine Tests
    • 4.2.3.2. X-ray
    • 4.2.3.3. Magnetic Resonance Imaging (MRI)
    • 4.2.3.4. Computed Tomography (CT or CAT) Scan
    • 4.2.3.5. Positron Emission Tomography (PET) or PET-CT Scan
    • 4.2.3.6. Bone Marrow Aspiration and Biopsy
    • 4.2.3.7. Fat Pad Aspirate
    • 4.2.3.8. Biomarker Testing of the Tumor
    • 4.2.3.9. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia Pacific (APAC)
    • 4.2.4.4. Latin America (LATAM)
    • 4.2.4.5. Middle East and Africa (MEA)

5. North America Multiple Myeloma Market

• 5.1. Market Size & Forecast, 2019-2029
  • 5.1.1. By Value (USD Billion)
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Treatment
  • 5.2.3. By Diagnosis
  • 5.2.4. By Country
    • 5.2.4.1. United States
    • 5.2.4.1.1. By Type
    • 5.2.4.1.2. By Treatment
    • 5.2.4.1.3. By Diagnosis
    • 5.2.4.2. Canada
    • 5.2.4.2.1. By Type
    • 5.2.4.2.2. By Treatment
    • 5.2.4.2.3. By Diagnosis

6. Europe Multiple Myeloma Market

• 6.1. Market Size & Forecast, 2019-2029
  • 6.1.1. By Value (USD Billion)
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Diagnosis
  • 6.2.4. By Country
    • 6.2.4.1. Germany
    • 6.2.4.1.1. By Type
    • 6.2.4.1.2. By Treatment
    • 6.2.4.1.3. By Diagnosis
    • 6.2.4.2. United Kingdom
    • 6.2.4.2.1. By Type
    • 6.2.4.2.2. By Treatment
    • 6.2.4.2.3. By Diagnosis
    • 6.2.4.3. Italy
    • 6.2.4.3.1. By Type
    • 6.2.4.3.2. By Treatment
    • 6.2.4.3.3. By Diagnosis
    • 6.2.4.4. France
    • 6.2.4.4.1. By Type
    • 6.2.4.4.2. By Treatment
    • 6.2.4.4.3. By Diagnosis
    • 6.2.4.5. Spain
    • 6.2.4.5.1. By Type
    • 6.2.4.5.2. By Treatment
    • 6.2.4.5.3. By Diagnosis
    • 6.2.4.6. Belgium
    • 6.2.4.6.1. By Type
    • 6.2.4.6.2. By Treatment
    • 6.2.4.6.3. By Diagnosis
    • 6.2.4.7. Russia
    • 6.2.4.7.1. By Type
    • 6.2.4.7.2. By Treatment
    • 6.2.4.7.3. By Diagnosis
    • 6.2.4.8. The Netherlands
    • 6.2.4.8.1. By Type
    • 6.2.4.8.2. By Treatment
    • 6.2.4.8.3. By Diagnosis
    • 6.2.4.9. Rest of Europe
    • 6.2.4.9.1. By Type
    • 6.2.4.9.2. By Treatment
    • 6.2.4.9.3. By Diagnosis

7. Asia-Pacific Multiple Myeloma Market

• 7.1. Market Size & Forecast, 2019-2029
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Diagnosis
  • 7.2.4. By Country
    • 7.2.4.1. China
    • 7.2.4.1.1. By Type
    • 7.2.4.1.2. By Treatment
    • 7.2.4.1.3. By Diagnosis
    • 7.2.4.2. India
    • 7.2.4.2.1. By Type
    • 7.2.4.2.2. By Treatment
    • 7.2.4.2.3. By Diagnosis
    • 7.2.4.3. Japan
    • 7.2.4.3.1. By Type
    • 7.2.4.3.2. By Treatment
    • 7.2.4.3.3. By Diagnosis
    • 7.2.4.4. South Korea
    • 7.2.4.4.1. By Type
    • 7.2.4.4.2. By Treatment
    • 7.2.4.4.3. By Diagnosis
    • 7.2.4.5. Australia & New Zealand
    • 7.2.4.5.1. By Type
    • 7.2.4.5.2. By Treatment
    • 7.2.4.5.3. By Diagnosis
    • 7.2.4.6. Indonesia
    • 7.2.4.6.1. By Type
    • 7.2.4.6.2. By Treatment
    • 7.2.4.6.3. By Diagnosis
    • 7.2.4.7. Malaysia
    • 7.2.4.7.1. By Type
    • 7.2.4.7.2. By Treatment
    • 7.2.4.7.3. By Diagnosis
    • 7.2.4.8. Singapore
    • 7.2.4.8.1. By Type
    • 7.2.4.8.2. By Treatment
    • 7.2.4.8.3. By Diagnosis
    • 7.2.4.9. Vietnam
    • 7.2.4.9.1. By Type
    • 7.2.4.9.2. By Treatment
    • 7.2.4.9.3. By Diagnosis
    • 7.2.4.10. Rest of APAC
    • 7.2.4.10.1. By Type
    • 7.2.4.10.2. By Treatment
    • 7.2.4.10.3. By Diagnosis

8. Latin America Multiple Myeloma Market

• 8.1. Market Size & Forecast, 2019-2029
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Diagnosis
  • 8.2.4. By Country
    • 8.2.4.1. Brazil
    • 8.2.4.1.1. By Type
    • 8.2.4.1.2. By Treatment
    • 8.2.4.1.3. By Diagnosis
    • 8.2.4.2. Mexico
    • 8.2.4.2.1. By Type
    • 8.2.4.2.2. By Treatment
    • 8.2.4.2.3. By Diagnosis
    • 8.2.4.3. Argentina
    • 8.2.4.3.1. By Type
    • 8.2.4.3.2. By Treatment
    • 8.2.4.3.3. By Diagnosis
    • 8.2.4.4. Peru
    • 8.2.4.4.1. By Type
    • 8.2.4.4.2. By Treatment
    • 8.2.4.4.3. By Diagnosis
    • 8.2.4.5. Rest of LATAM
    • 8.2.4.5.1. By Type
    • 8.2.4.5.2. By Treatment
    • 8.2.4.5.3. By Diagnosis

9. Middle East & Africa Multiple Myeloma Market

• 9.1. Market Size & Forecast, 2019-2029
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Diagnosis
  • 9.2.4. By Country
    • 9.2.4.1. Saudi Arabia
    • 9.2.4.1.1. By Type
    • 9.2.4.1.2. By Treatment
    • 9.2.4.1.3. By Diagnosis
    • 9.2.4.2. UAE
    • 9.2.4.2.1. By Type
    • 9.2.4.2.2. By Treatment
    • 9.2.4.2.3. By Diagnosis
    • 9.2.4.3. Qatar
    • 9.2.4.3.1. By Type
    • 9.2.4.3.2. By Treatment
    • 9.2.4.3.3. By Diagnosis
    • 9.2.4.4. Kuwait
    • 9.2.4.4.1. By Type
    • 9.2.4.4.2. By Treatment
    • 9.2.4.4.3. By Diagnosis
    • 9.2.4.5. South Africa
    • 9.2.4.5.1. By Type
    • 9.2.4.5.2. By Treatment
    • 9.2.4.5.3. By Diagnosis
    • 9.2.4.6. Nigeria
    • 9.2.4.6.1. By Type
    • 9.2.4.6.2. By Treatment
    • 9.2.4.6.3. By Diagnosis
    • 9.2.4.7. Algeria
    • 9.2.4.7.1. By Type
    • 9.2.4.7.2. By Treatment
    • 9.2.4.7.3. By Diagnosis
    • 9.2.4.8. Rest of MEA
    • 9.2.4.8.1. By Type
    • 9.2.4.8.2. By Treatment
    • 9.2.4.8.3. By Diagnosis

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Multiple Myeloma Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Multiple Myeloma Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 12.1. Sanofi
• 12.2. Pfizer Inc.
• 12.3. GlaxoSmithKline plc
• 12.4. Novartis AG
• 12.5. Bayer AG
• 12.6. Eli Lilly and Company
• 12.7. Merck & Co., Inc.
• 12.8. AstraZeneca
• 12.9. Bristol-Myers Squibb Company
• 12.10. AbbVie Inc.
• 12.11. Teva Pharmaceutical Industries Ltd
• 12.12. ONO Pharmaceutical Co., Ltd
• 12.13. Takeda Pharmaceutical Company Ltd
• 12.14. Roche Group
• 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations